Patents by Inventor Joseph P. Lyssikatos

Joseph P. Lyssikatos has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Compounds, compositions and methods
    Patent number: 10131676
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Grant
    Filed: September 29, 2017
    Date of Patent: November 20, 2018
    Assignee: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • COMPOUND, COMPOSITIONS, AND METHODS
    Publication number: 20180327391
    Abstract: Compounds having activity as LRRK2 inhibitors are disclosed. The compounds are of formula (I) including stereoisomers, tautomers, pharmaceutically acceptable salts and prodrugs thereof. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds are also disclosed.
    Type: Application
    Filed: November 18, 2016
    Publication date: November 15, 2018
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • INHIBITING AGENTS FOR BRUTON'S TYROSINE KINASE
    Publication number: 20180297992
    Abstract: Provided are compounds of Formula (I), or pharmaceutically acceptable salts thereof, and methods for their use and production.
    Type: Application
    Filed: April 13, 2018
    Publication date: October 18, 2018
    Inventors: Brian T. Hopkins, Bin Ma, Robin Prince, Isaac Marx, Joseph P. Lyssikatos, Fengmei Zheng, Matthew Peterson, Daniel B. Patience
  • SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
    Publication number: 20180282272
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: June 6, 2018
    Publication date: October 4, 2018
    Applicant: Genentech, Inc.
    Inventors: Huifen CHEN, Yanyan CHU, Steven DO, Anthony ESTRADA, Baihua HU, Aleksandr KOLESNIKOV, Xingyu LIN, Joseph P. LYSSIKATOS, Daniel SHORE, Vishal VERMA, Lan WANG, Guosheng WU, Po-wai YUEN
  • N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
    Publication number: 20180271824
    Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
    Type: Application
    Filed: May 9, 2018
    Publication date: September 27, 2018
    Inventors: Joseph P. LYSSIKATOS, Julie Marie HICKS, Fredrik P. MARMSATER, Qian ZHAO
  • Biaryl inhibitors of bruton's tyrosine kinase
    Patent number: 10081619
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: September 8, 2017
    Date of Patent: September 25, 2018
    Assignee: BIOGEN MA INC.
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Lihong Sun, Lei Zhang, Gnanasambandam Kumaravel, Joseph P. Lyssikatos, Kevin Koch, Hua Miao
  • Deuterated compounds and uses thereof
    Patent number: 10076581
    Abstract: The present invention relates to deuterated and optionally detectably labeled compounds of formula (I) and formula (V): and salts thereof, wherein R1, R2, A, and X10-X19 have any of the values defined in the specification. Also included are pharmaceutical compositions comprising such compounds and salts, and methods of using such compounds and salts as imaging agents.
    Type: Grant
    Filed: January 26, 2016
    Date of Patent: September 18, 2018
    Assignee: Genentech, Inc.
    Inventors: Jan Marik, Joseph P. Lyssikatos, Simon Williams
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20180208582
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: March 21, 2018
    Publication date: July 26, 2018
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Mitotic kinesin inhibitors and methods of use thereof
    Patent number: 10017482
    Abstract: This invention relates to inhibitors of mitotic kinesins, particularly KSP, and methods for producing these inhibitors.
    Type: Grant
    Filed: November 21, 2016
    Date of Patent: July 10, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Jeremy Hans, Eli M. Wallace, Qian Zhao, Joseph P. Lyssikatos, Thomas D. Aicher, Ellen Laird, John Robinson, Shelley Allen
  • SUBSTITUTED HETEROCYCLIC SULFONAMIDE COMPOUNDS USEFUL AS TRPA1 MODULATORS
    Publication number: 20180118680
    Abstract: The invention is concerned with the compounds of formula I or II: and salts thereof. In addition, the present invention relates to methods of manufacturing and methods of using the compounds of formula I or II as well as pharmaceutical compositions containing such compounds. The compounds may be useful in treating diseases and conditions mediated by TRPA1, such as pain.
    Type: Application
    Filed: December 21, 2017
    Publication date: May 3, 2018
    Applicant: Genentech, Inc.
    Inventors: Huifen Chen, Yanyan Chu, Steven Do, Anthony Estrada, Baihua Hu, Aleksandr Kolesnikov, Xingyu Lin, Joseph P. Lyssikatos, Daniel Shore, Vishal Verma, Lan Wang, Guosheng Wu, Po-wai Yuen
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20180099981
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: September 29, 2017
    Publication date: April 12, 2018
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • BIARYL INHIBITORS OF BRUTON'S TYROSINE KINASE
    Publication number: 20180093973
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Application
    Filed: December 20, 2017
    Publication date: April 5, 2018
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Lihong Sun, Lei Zhang, Gnanasambandam Kumaravel, Joseph P. Lyssikatos, Kevin Koch, Hua Miao
  • Compounds, compositions, and methods
    Patent number: 9932325
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Grant
    Filed: October 25, 2017
    Date of Patent: April 3, 2018
    Assignee: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20180051009
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: October 25, 2017
    Publication date: February 22, 2018
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • COMPOUNDS, COMPOSITIONS AND METHODS
    Publication number: 20180022759
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Application
    Filed: September 29, 2017
    Publication date: January 25, 2018
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • COMPOUNDS, COMPOSITIONS, AND METHODS
    Publication number: 20170362206
    Abstract: The present disclosure relates generally to LRRK2 inhibitors, or a pharmaceutically acceptable salt, deuterated analog, prodrug, tautomer, stereoisomer, or mixture of stereoisomers thereof, and methods of making and using thereof.
    Type: Application
    Filed: June 15, 2017
    Publication date: December 21, 2017
    Applicant: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Joseph P. Lyssikatos, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Compounds, compositions and methods
    Patent number: 9815850
    Abstract: The present disclosure relates generally to compounds and compositions, and their use as kinase inhibitors.
    Type: Grant
    Filed: February 3, 2017
    Date of Patent: November 14, 2017
    Assignee: Denali Therapeutics Inc.
    Inventors: Anthony A. Estrada, Jianwen A. Feng, Brian Fox, Colin Philip Leslie, Joseph P. Lyssikatos, Alfonso Pozzan, Zachary K. Sweeney, Javier de Vicente Fidalgo
  • Biaryl inhibitors of Bruton's tyrosine kinase
    Patent number: 9809577
    Abstract: The present invention provides compounds and compositions thereof which are useful as inhibitors of Bruton's tyrosine kinase and which exhibit desirable characteristics for the same.
    Type: Grant
    Filed: December 11, 2014
    Date of Patent: November 7, 2017
    Assignee: Biogen MA Inc.
    Inventors: Brian T. Hopkins, Bin Ma, Timothy Raymond Chan, Lihong Sun, Lei Zhang, Gnanasambandam Kumaravel, Joseph P. Lyssikatos, Kevin Koch, Hua Miao
  • PYRAZOLOPYRIMIDINE JAK INHIBITOR COMPOUNDS AND METHODS
    Publication number: 20170283424
    Abstract: A compound of Formula I, enantiomers, diasteriomers, tautomers or pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are defined herein, are useful as inhibitors of one or more Janus kinases. A pharmaceutical composition that includes a compound of Formula I and a pharmaceutically acceptable carrier, adjuvant or vehicle, and methods of treating or lessening the severity of a disease or condition responsive to the inhibition of a Janus kinase activity in a patient are disclosed.
    Type: Application
    Filed: June 20, 2017
    Publication date: October 5, 2017
    Applicant: Genentech, Inc.
    Inventors: Paul Gibbons, Emily Hanan, Wendy Liu, Joseph P. Lyssikatos, Steven R. Magnuson, Rohan Mendonca, Richard Pastor, Thomas E. Rawson, Michael Siu, Mark E. Zak, Aihe Zhou, Bing-Yan Zhu, Christopher Hurley
  • N4-PHENYL-QUINAZOLINE-4-AMINE DERIVATIVES AND RELATED COMPOUNDS AS ERBB TYPE I RECEPTOR TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES
    Publication number: 20170252317
    Abstract: This invention provides compounds of Formula I wherein B, G, A, E, R1, R2, R3, m and n are as defined herein, which are useful as type I receptor tyrosine kinase inhibitors, and methods of use thereof in the treatment of hyperproliferative disorders in mammals.
    Type: Application
    Filed: May 19, 2017
    Publication date: September 7, 2017
    Inventors: Joseph P. LYSSIKATOS, Julie Marie HICKS, Fredrik P. MARMSATER, Qian ZHAO